NCT06814522 Psilocybin-Assisted Therapy for Physician Well-Being and Burnout
| NCT ID | NCT06814522 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | University of California, San Diego |
| Condition | Burnout |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2025-01-13 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.
Eligibility Criteria
Inclusion Criteria: 1. Faculty physician, aged 21-70. Volunteer faculty are not included 2. Meets criteria for physician burnout 3. Experiencing symptoms of burnout for \>6 months 4. Able to complete all required study visits 5. Not previously diagnosed with a serious mental illness (including schizophrenia, bipolar disorder, and severe depression), or substance use disorder as confirmed in clinical interview 6. Not currently taking any psychotropic medications or nonpsychotropic medication that may be associated with serotonin syndrome, such as serotonin reuptake inhibitors (SSRI or SNRI), dextromethorphan, linezolid, tramadol, meperidine Exclusion Criteria: 1. Previous inpatient psychiatric hospitalization(s) 2. Previously diagnosed with a psychotic disorder (schizophrenia, schizoaffective disorder, or other psychotic spectrum disorder), bipolar spectrum disorder, personality disorder (borderline personality disorder, antisocial personality disorder, or other severe personality disorders), any severe psychiatric disorder. 3. Exhibiting elevated suicide risk 4. First degree family history of psychosis or bipolar disorder 5. Prior exposure to psilocybin or other psychedelic compounds in the previous 5 years 6. Currently pregnant, nursing, planning pregnancy, engaging in sexual intercourse without effective contraceptive method in last three months 7. Those who plan to donate sperm within three months following the study. 8. Known cardiovascular disease including history of stroke, myocardial infarction, uncontrolled hypertension, valvular heart disease, tachycardia, elongated QT interval, or clinically significant arrythmia. 9. History of seizure disorder 10. Use of recreational illicit drugs 11. Clinically concerning results from vital signs, ECG, physical examination, or laboratory tests during screening 12. Any other clinically significant illnesses deemed to pose risk for the participant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06814522 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Burnout. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06814522 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06814522 currently recruiting?
Yes, NCT06814522 is actively recruiting participants. Contact the research team at vyn014@health.ucsd.edu for enrollment information.
Where is the NCT06814522 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT06814522 clinical trial?
NCT06814522 is sponsored by University of California, San Diego. The trial plans to enroll 30 participants.